{
    "nct_id": "NCT03242824",
    "official_title": "MC167B: Pilot Study Investigating the Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma",
    "inclusion_criteria": "Inclusion Criteria\n\n* Age > or equal to 18 years\n* ECOG PS < or equal to 3\n* Histologically confirmed or radiographic evidence of recurrent/progressive glioma.\n* History of radiation therapy to the brain for prior diagnosis of glioma\n* Planned radiation treatments at Mayo Clinic Rochester\n* Provide informed written consent\n* Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB number 15-000136 (blood draw optional)\n* Willing to return to enrolling institution for follow-up during Active Monitoring Phase of the study.\n\nExclusion Criteria\n\n* More than one prior course of radiotherapy or prior prescription doses exceeding 60 Gy to re-irradiation target volumes\n* Unable to undergo MRI scans with contrast\n* Unable to undergo an 18F-DOPA-PET scan (e.g., Parkinson's Disease, taking anti dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists.)\n\nNote: Other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline). If a patient is on any of these drugs, list which ones on the On-Study form.\n\n-Any of the following:\n\n* Pregnant women\n* Nursing women\n* Men or women of childbearing potential who are unwilling to employ adequate contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}